AWS
NBIX icon

Atria Wealth Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Atria Wealth Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,641
Closed -$369K – 1947
2023
Q1 		$369K Sell
3,641
-12
-0.3% -$1.25K 0.01% 1308
2022
Q4 		$436K Buy
3,653
+56
+2% +$6.56K 0.01% 1158
2022
Q3 		$382K Sell
3,597
-431
-11% -$43.7K 0.01% 1169
2022
Q2 		$393K Sell
4,028
-568
-12% -$52.4K 0.01% 1080
2022
Q1 		$431K Buy
+4,596
New +$390K 0.01% 1148

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atria Wealth Solutions's NBIX Position: Q2 2023 in Review

Atria Wealth Solutions sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 3,641 shares — an estimated $369K sold.

Atria Wealth Solutions first reported a position in NBIX in Q1 2022 and held it in 5 quarters. The position peaked at $436K in Q4 2022. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Atria Wealth Solutions reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • Atria Wealth Solutions sold 3,641 Neurocrine Biosciences shares in Q2 2023, an estimated $369K.
  • Atria Wealth Solutions first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 5 quarters.
  • Atria Wealth Solutions's Neurocrine Biosciences position peaked at $436K in Q4 2022.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Atria Wealth Solutions's 13F filing for Q2 2023, filed 3 Aug 2023.